# Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies
Canonical URL: https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-completes-acquisition-of-optinose-creating-an-expanded-portfolio-of-specialty-therapies
Ticker: PRTK
Company: Paratek Pharmaceuticals
Source: Paratek Pharmaceuticals
Published: 2025-05-21 08:26 EST
Original Source URL: https://www.pressviewer.com
## Summary

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="left">BOSTON, May 21, 2025 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty 

## Article Body
BOSTON, May  21, 2025  (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a privately held pharmaceutical company focused on the development and commercialization of specialty therapies for specialists and community care providers, that address important medical and public health threats, today announced that the Company has completed its acquisition...
## Recent Company News
- 2026-04-16 07:30 EST — [Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at ESCMID Global 2026](https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-to-present-new-data-on-nuzyrar-omadacycline-at-escmid-global-2026) — Source: Paratek Pharmaceuticals
- 2026-03-18 07:00 EST — [Paratek Pharmaceuticals Completes Combination with Radius Health, Expanding Its Multi-Product Specialty Commercial Platform](https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-completes-combination-with-radius-health-expanding-its-multi-product-specialty-commercial-platform) — Source: Paratek Pharmaceuticals
- 2026-02-24 07:30 EST — [Paratek Pharmaceuticals Announces Positive Results for NUZYRA® Therapeutic Efficacy Studies in Inhalation Anthrax Triggering Additional Procurement under BARDA Project BioShield Contract](https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-announces-positive-results-for-nuzyrar-therapeutic-efficacy-studies-in-inhalation-anthrax-triggering-additional-procurement-under-barda-project-bioshield-contract) — Source: Paratek Pharmaceuticals
- 2025-10-17 07:30 EST — [Paratek Pharmaceuticals to Present New Data on NUZYRA® (omadacycline) at IDWeek 2025 and CHEST 2025](https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-to-present-new-data-on-nuzyrar-omadacycline-at-idweek-2025-and-chest-2025) — Source: Paratek Pharmaceuticals
- 2025-05-21 08:26 EST — [Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies](https://biopharmsignal.com/news/PRTK/paratek-pharmaceuticals-completes-acquisition-of-optinose-creating-an-expanded-portfolio-of-specialty-therapies) — Source: Paratek Pharmaceuticals
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)